Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


Articles published in PLoS One

Retrieve available abstracts of 360 articles:
HTML format
Text format



Single Articles


    January 2017
  1. ROCHA-BRISCHILIARI SC, Oliveira RR, Andrade L, Brischiliari A, et al
    The Rise in Mortality from Breast Cancer in Young Women: Trend Analysis in Brazil.
    PLoS One. 2017;12:e0168950.
    PubMed     Text format     Abstract available


  2. WANG K, Ren Y, He J
    Cavity Shaving plus Lumpectomy versus Lumpectomy Alone for Patients with Breast Cancer Undergoing Breast-Conserving Surgery: A Systematic Review and Meta-Analysis.
    PLoS One. 2017;12:e0168705.
    PubMed     Text format     Abstract available


  3. WU W, Ma J, Shao N, Shi Y, et al
    Co-Targeting IGF-1R and Autophagy Enhances the Effects of Cell Growth Suppression and Apoptosis Induced by the IGF-1R Inhibitor NVP-AEW541 in Triple-Negative Breast Cancer Cells.
    PLoS One. 2017;12:e0169229.
    PubMed     Text format     Abstract available


  4. CHEN Q, Weng Z, Lu Y, Jia Y, et al
    An Experimental Analysis of the Molecular Effects of Trastuzumab (Herceptin) and Fulvestrant (Falsodex), as Single Agents or in Combination, on Human HR+/HER2+ Breast Cancer Cell Lines and Mouse Tumor Xenografts.
    PLoS One. 2017;12:e0168960.
    PubMed     Text format     Abstract available


  5. MAKHOUL I, Todorova VK, Siegel ER, Erickson SW, et al
    Germline Genetic Variants in TEK, ANGPT1, ANGPT2, MMP9, FGF2 and VEGFA Are Associated with Pathologic Complete Response to Bevacizumab in Breast Cancer Patients.
    PLoS One. 2017;12:e0168550.
    PubMed     Text format     Abstract available


  6. DIAS K, Dvorkin-Gheva A, Hallett RM, Wu Y, et al
    Claudin-Low Breast Cancer; Clinical & Pathological Characteristics.
    PLoS One. 2017;12:e0168669.
    PubMed     Text format     Abstract available


  7. LIU Y, Zhang Y, Li Q, Li J, et al
    MiRNAs Predict the Prognosis of Patients with Triple Negative Breast Cancer: A Meta-Analysis.
    PLoS One. 2017;12:e0170088.
    PubMed     Text format     Abstract available


  8. SINHA AK, Patel JR, Shen Y, Ueno NT, et al
    Location of Receipt of Initial Treatment and Outcomes in Long-Term Breast Cancer Survivors.
    PLoS One. 2017;12:e0170081.
    PubMed     Text format     Abstract available


  9. VITALI F, Cohen LD, Demartini A, Amato A, et al
    Correction: A Network-Based Data Integration Approach to Support Drug Repurposing and Multi-Target Therapies in Triple Negative Breast Cancer.
    PLoS One. 2017;12:e0170363.
    PubMed     Text format     Abstract available


  10. BRONSVELD HK, Jensen V, Vahl P, De Bruin ML, et al
    Diabetes and Breast Cancer Subtypes.
    PLoS One. 2017;12:e0170084.
    PubMed     Text format     Abstract available


  11. KIM YC, Soliman AS, Cui J, Ramadan M, et al
    Unique Features of Germline Variation in Five Egyptian Familial Breast Cancer Families Revealed by Exome Sequencing.
    PLoS One. 2017;12:e0167581.
    PubMed     Text format     Abstract available


  12. SINGH A, Sharma RK, Chagtoo M, Agarwal G, et al
    1H NMR Metabolomics Reveals Association of High Expression of Inositol 1, 4, 5 Trisphosphate Receptor and Metabolites in Breast Cancer Patients.
    PLoS One. 2017;12:e0169330.
    PubMed     Text format     Abstract available


  13. HATOUM D, Yagoub D, Ahadi A, Nassif NT, et al
    Annexin/S100A Protein Family Regulation through p14ARF-p53 Activation: A Role in Cell Survival and Predicting Treatment Outcomes in Breast Cancer.
    PLoS One. 2017;12:e0169925.
    PubMed     Text format     Abstract available


  14. LI Y, Wang J, Lin F, Yang Y, et al
    A Methodology for Cancer Therapeutics by Systems Pharmacology-Based Analysis: A Case Study on Breast Cancer-Related Traditional Chinese Medicines.
    PLoS One. 2017;12:e0169363.
    PubMed     Text format     Abstract available


  15. HUANG MW, Chen CW, Lin WC, Ke SW, et al
    SVM and SVM Ensembles in Breast Cancer Prediction.
    PLoS One. 2017;12:e0161501.
    PubMed     Text format     Abstract available


  16. THIRUKKUMARAN C, Shi ZQ, Thirukkumaran P, Luider J, et al
    PUMA and NF-kB Are Cell Signaling Predictors of Reovirus Oncolysis of Breast Cancer.
    PLoS One. 2017;12:e0168233.
    PubMed     Text format     Abstract available


  17. PILLAI SG, Zhu P, Siddappa CM, Adams DL, et al
    Enrichment and Molecular Analysis of Breast Cancer Disseminated Tumor Cells from Bone Marrow Using Microfiltration.
    PLoS One. 2017;12:e0170761.
    PubMed     Text format     Abstract available


  18. PETERS IT, van Zwet EW, Smit VT, Liefers GJ, et al
    Prevalence and Risk Factors of Ovarian Metastases in Breast Cancer Patients < 41 Years of Age in the Netherlands: A Nationwide Retrospective Cohort Study.
    PLoS One. 2017;12:e0168277.
    PubMed     Text format     Abstract available


  19. SIGLEY J, Jarzen J, Scarpinato K, Guthold M, et al
    Diffusion and Binding of Mismatch Repair Protein, MSH2, in Breast Cancer Cells at Different Stages of Neoplastic Transformation.
    PLoS One. 2017;12:e0170414.
    PubMed     Text format     Abstract available


  20. DENG J, Yang M, Jiang R, An N, et al
    Long Non-Coding RNA HOTAIR Regulates the Proliferation, Self-Renewal Capacity, Tumor Formation and Migration of the Cancer Stem-Like Cell (CSC) Subpopulation Enriched from Breast Cancer Cells.
    PLoS One. 2017;12:e0170860.
    PubMed     Text format     Abstract available


  21. YIN K, Liu Y, Chu M, Wang Y, et al
    TFDP3 Regulates Epithelial-Mesenchymal Transition in Breast Cancer.
    PLoS One. 2017;12:e0170573.
    PubMed     Text format     Abstract available


  22. DALM SU, Schrijver WA, Sieuwerts AM, Look MP, et al
    Prospects of Targeting the Gastrin Releasing Peptide Receptor and Somatostatin Receptor 2 for Nuclear Imaging and Therapy in Metastatic Breast Cancer.
    PLoS One. 2017;12:e0170536.
    PubMed     Text format     Abstract available


  23. PIRES BR, Mencalha AL, Ferreira GM, de Souza WF, et al
    NF-kappaB Is Involved in the Regulation of EMT Genes in Breast Cancer Cells.
    PLoS One. 2017;12:e0169622.
    PubMed     Text format     Abstract available


  24. ZIV E, Tice JA, Sprague B, Vachon CM, et al
    Using Breast Cancer Risk Associated Polymorphisms to Identify Women for Breast Cancer Chemoprevention.
    PLoS One. 2017;12:e0168601.
    PubMed     Text format     Abstract available


  25. LINDBERG P, Netter P, Koller M, Steinger B, et al
    Breast cancer survivors` recollection of their quality of life: Identifying determinants of recall bias in a longitudinal population-based trial.
    PLoS One. 2017;12:e0171519.
    PubMed     Text format     Abstract available


  26. STRUMYLAITE L, Kregzdyte R, Poskiene L, Bogusevicius A, et al
    Association between lifetime exposure to passive smoking and risk of breast cancer subtypes defined by hormone receptor status among non-smoking Caucasian women.
    PLoS One. 2017;12:e0171198.
    PubMed     Text format     Abstract available


  27. KIM TH, Chang JS, Park KS, Park J, et al
    Effects of exercise training on circulating levels of Dickkpof-1 and secreted frizzled-related protein-1 in breast cancer survivors: A pilot single-blind randomized controlled trial.
    PLoS One. 2017;12:e0171771.
    PubMed     Text format     Abstract available


  28. BALEKOUZOU A, Yin P, Afewerky HK, Bekolo C, et al
    Behavioral risk factors of breast cancer in Bangui of Central African Republic: A retrospective case-control study.
    PLoS One. 2017;12:e0171154.
    PubMed     Text format     Abstract available


  29. AZIZ S, Wik E, Knutsvik G, Klingen TA, et al
    Extra-nodal extension is a significant prognostic factor in lymph node positive breast cancer.
    PLoS One. 2017;12:e0171853.
    PubMed     Text format     Abstract available


  30. GOMES-ROCHETTE NF, Souza LS, Tommasi BO, Pedrosa DF, et al
    Association of PvuII and XbaI polymorphisms on estrogen receptor alpha (ESR1) gene to changes into serum lipid profile of post-menopausal women: Effects of aging, body mass index and breast cancer incidence.
    PLoS One. 2017;12:e0169266.
    PubMed     Text format     Abstract available


  31. AUGUSTE A, Cortet M, Dabakuyo-Yonli TS, Launay L, et al
    Breast cancer subtype of French women is not influenced by socioeconomic status: A population-based-study.
    PLoS One. 2017;12:e0170069.
    PubMed     Text format     Abstract available


  32. HUANG NS, Quan CL, Mo M, Chen JJ, et al
    A prospective study of breast anthropomorphic measurements, volume and ptosis in 605 Asian patients with breast cancer or benign breast disease.
    PLoS One. 2017;12:e0172122.
    PubMed     Text format     Abstract available


  33. AKUOKO CP, Armah E, Sarpong T, Quansah DY, et al
    Barriers to early presentation and diagnosis of breast cancer among African women living in sub-Saharan Africa.
    PLoS One. 2017;12:e0171024.
    PubMed     Text format     Abstract available


  34. TERRENATO I, D'Alicandro V, Casini B, Perracchio L, et al
    A cut-off of 2150 cytokeratin 19 mRNA copy number in sentinel lymph node may be a powerful predictor of non-sentinel lymph node status in breast cancer patients.
    PLoS One. 2017;12:e0171517.
    PubMed     Text format     Abstract available


  35. JANG MH, Kim HJ, Chung YR, Lee Y, et al
    A comparison of Ki-67 counting methods in luminal Breast Cancer: The Average Method vs. the Hot Spot Method.
    PLoS One. 2017;12:e0172031.
    PubMed     Text format     Abstract available


  36. CONTE F, Fiscon G, Chiara M, Colombo T, et al
    Role of the long non-coding RNA PVT1 in the dysregulation of the ceRNA-ceRNA network in human breast cancer.
    PLoS One. 2017;12:e0171661.
    PubMed     Text format     Abstract available


  37. KASHIWAGI S, Asano Y, Goto W, Takada K, et al
    Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer.
    PLoS One. 2017;12:e0170634.
    PubMed     Text format     Abstract available


  38. FAN M, Li H, Wang S, Zheng B, et al
    Radiomic analysis reveals DCE-MRI features for prediction of molecular subtypes of breast cancer.
    PLoS One. 2017;12:e0171683.
    PubMed     Text format     Abstract available


  39. TAKEDA T, Yamamoto H, Kanzaki H, Suzawa K, et al
    Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
    PLoS One. 2017;12:e0171356.
    PubMed     Text format     Abstract available


  40. SIEUWERTS AM, Schrijver WA, Dalm SU, de Weerd V, et al
    Progressive APOBEC3B mRNA expression in distant breast cancer metastases.
    PLoS One. 2017;12:e0171343.
    PubMed     Text format     Abstract available


  41. QIAN XL, Zhang J, Li PZ, Lang RG, et al
    Dasatinib inhibits c-src phosphorylation and prevents the proliferation of Triple-Negative Breast Cancer (TNBC) cells which overexpress Syndecan-Binding Protein (SDCBP).
    PLoS One. 2017;12:e0171169.
    PubMed     Text format     Abstract available


  42. QIAO W, Pan L, Kou C, Li K, et al
    Prognostic and clinicopathological value of poly (adenosine diphosphate-ribose) polymerase expression in breast cancer: A meta-analysis.
    PLoS One. 2017;12:e0172413.
    PubMed     Text format     Abstract available


  43. KIM MH, Lee KY, Park S, Kim SI, et al
    Effects of systemic lidocaine versus magnesium administration on postoperative functional recovery and chronic pain in patients undergoing breast cancer surgery: A prospective, randomized, double-blind, comparative clinical trial.
    PLoS One. 2017;12:e0173026.
    PubMed     Text format     Abstract available


  44. GSCHWANTLER-KAULICH D, Tan YY, Fuchs EM, Hudelist G, et al
    PTEN expression as a predictor for the response to trastuzumab-based therapy in Her-2 overexpressing metastatic breast cancer.
    PLoS One. 2017;12:e0172911.
    PubMed     Text format     Abstract available


  45. CLARKE CS, Hunter RM, Shemilt I, Serra-Sastre V, et al
    Multi-arm Cost-Effectiveness Analysis (CEA) comparing different durations of adjuvant trastuzumab in early breast cancer, from the English NHS payer perspective.
    PLoS One. 2017;12:e0172731.
    PubMed     Text format     Abstract available


  46. CHUNG IY, Lee JW, Lee JS, Park YR, et al
    Interaction between body mass index and hormone-receptor status as a prognostic factor in lymph-node-positive breast cancer.
    PLoS One. 2017;12:e0170311.
    PubMed     Text format     Abstract available


  47. KAN-DAPAAH K, Rahbar N, Soboyejo W
    Polymeric composite devices for localized treatment of early-stage breast cancer.
    PLoS One. 2017;12:e0172542.
    PubMed     Text format     Abstract available


  48. ISLAM S, Dasgupta H, Roychowdhury A, Bhattacharya R, et al
    Study of association and molecular analysis of human papillomavirus in breast cancer of Indian patients: Clinical and prognostic implication.
    PLoS One. 2017;12:e0172760.
    PubMed     Text format     Abstract available


  49. SIMON M, Mesmar F, Helguero L, Williams C, et al
    Genome-wide effects of MELK-inhibitor in triple-negative breast cancer cells indicate context-dependent response with p53 as a key determinant.
    PLoS One. 2017;12:e0172832.
    PubMed     Text format     Abstract available


  50. PAN Y, Yuan Y, Liu G, Wei Y, et al
    P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients.
    PLoS One. 2017;12:e0172324.
    PubMed     Text format     Abstract available


  51. CURRY A, Khatri I, Kos O, Zhu F, et al
    Importance of CD200 expression by tumor or host cells to regulation of immunotherapy in a mouse breast cancer model.
    PLoS One. 2017;12:e0171586.
    PubMed     Text format     Abstract available


  52. LEE J, Kim HH, Ro SM, Yang JH, et al
    Capecitabine and cisplatin (XP) combination systemic chemotherapy in heavily pre-treated HER2 negative metastatic breast cancer.
    PLoS One. 2017;12:e0171605.
    PubMed     Text format     Abstract available


  53. SON SH, Choi KH, Kim SW
    Dosimetric comparison of simultaneous integrated boost with whole-breast irradiation for early breast cancer.
    PLoS One. 2017;12:e0173552.
    PubMed     Text format     Abstract available


  54. MENNING S, de Ruiter MB, Veltman DJ, Boogerd W, et al
    Changes in brain activation in breast cancer patients depend on cognitive domain and treatment type.
    PLoS One. 2017;12:e0171724.
    PubMed     Text format     Abstract available


  55. ZAK M, Biskup M, Macek P, Krol H, et al
    Identifying predictive motor factors for falls in post-menopausal breast cancer survivors.
    PLoS One. 2017;12:e0173970.
    PubMed     Text format     Abstract available


  56. TOSCANI AM, Sampayo RG, Barabas FM, Fuentes F, et al
    Distinct ErbB2 receptor populations differentially interact with beta1 integrin in breast cancer cell models.
    PLoS One. 2017;12:e0174230.
    PubMed     Text format     Abstract available



  57. Correction: Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
    PLoS One. 2017;12:e0174493.
    PubMed     Text format     Abstract available


  58. HENG J, Guo X, Wu W, Wang Y, et al
    Integrated analysis of promoter mutation, methylation and expression of AKT1 gene in Chinese breast cancer patients.
    PLoS One. 2017;12:e0174022.
    PubMed     Text format     Abstract available


  59. HE X, Ye F, Zhao B, Tang H, et al
    Risk factors for delay of adjuvant chemotherapy in non-metastatic breast cancer patients: A systematic review and meta-analysis involving 186982 patients.
    PLoS One. 2017;12:e0173862.
    PubMed     Text format     Abstract available


  60. KLEBANER D, Hamilton-Dutoit S, Ahern T, Crawford A, et al
    Apolipoprotein D expression does not predict breast cancer recurrence among tamoxifen-treated patients.
    PLoS One. 2017;12:e0171453.
    PubMed     Text format     Abstract available


  61. NG CG, Mohamed S, Kaur K, Sulaiman AH, et al
    Perceived distress and its association with depression and anxiety in breast cancer patients.
    PLoS One. 2017;12:e0172975.
    PubMed     Text format     Abstract available


  62. LIU Y, Gu F, Liang J, Dai X, et al
    The efficacy and toxicity profile of metronomic chemotherapy for metastatic breast cancer: A meta-analysis.
    PLoS One. 2017;12:e0173693.
    PubMed     Text format     Abstract available


  63. AZAD AK, Lawen A, Keith JM
    Bayesian model of signal rewiring reveals mechanisms of gene dysregulation in acquired drug resistance in breast cancer.
    PLoS One. 2017;12:e0173331.
    PubMed     Text format     Abstract available


  64. SHEN CJ, Kuo YL, Chen CC, Chen MJ, et al
    MMP1 expression is activated by Slug and enhances multi-drug resistance (MDR) in breast cancer.
    PLoS One. 2017;12:e0174487.
    PubMed     Text format     Abstract available


  65. LEE J, Hong BS, Ryu HS, Lee HB, et al
    Transition into inflammatory cancer-associated adipocytes in breast cancer microenvironment requires microRNA regulatory mechanism.
    PLoS One. 2017;12:e0174126.
    PubMed     Text format     Abstract available


  66. CHANG YW, Singh KP
    Long-term exposure to estrogen enhances chemotherapeutic efficacy potentially through epigenetic mechanism in human breast cancer cells.
    PLoS One. 2017;12:e0174227.
    PubMed     Text format     Abstract available


  67. HAN J, Lee HB, Lee ES, Kang YJ, et al
    The treatment outcomes and the use of adjuvant therapies in breast cancer patients with severe co-morbidities.
    PLoS One. 2017;12:e0173721.
    PubMed     Text format     Abstract available


  68. ZHANG N, Fielding R, Soong I, Chan KK, et al
    Psychometric assessment of the Chinese version of the brief illness perception questionnaire in breast cancer survivors.
    PLoS One. 2017;12:e0174093.
    PubMed     Text format     Abstract available


  69. STANKEVICINS L, Barat A, Dessen P, Vassetzky Y, et al
    The microRNA-205-5p is correlated to metastatic potential of 21T series: A breast cancer progression model.
    PLoS One. 2017;12:e0173756.
    PubMed     Text format     Abstract available


  70. GUIMARAES E, Machado R, Fonseca MC, Franca A, et al
    Inositol 1, 4, 5-trisphosphate-dependent nuclear calcium signals regulate angiogenesis and cell motility in triple negative breast cancer.
    PLoS One. 2017;12:e0175041.
    PubMed     Text format     Abstract available


  71. ZHAO M, Howard EW, Guo Z, Parris AB, et al
    p53 pathway determines the cellular response to alcohol-induced DNA damage in MCF-7 breast cancer cells.
    PLoS One. 2017;12:e0175121.
    PubMed     Text format     Abstract available


  72. FANG S, Tian H, Li X, Jin D, et al
    Clinical application of a microfluidic chip for immunocapture and quantification of circulating exosomes to assist breast cancer diagnosis and molecular classification.
    PLoS One. 2017;12:e0175050.
    PubMed     Text format     Abstract available



  73. Retraction: Targeting 3-Phosphoinoside-Dependent Kinase-1 to Inhibit Insulin-Like Growth Factor-I Induced AKT and p70 S6 Kinase Activation in Breast Cancer Cells.
    PLoS One. 2017;12:e0175772.
    PubMed     Text format    



  74. Retraction: miR-221 Promotes Tumorigenesis in Human Triple Negative Breast Cancer Cells.
    PLoS One. 2017;12:e0175869.
    PubMed     Text format    


  75. KIM MS, Kim SY, Kim JH, Park B, et al
    Depression in breast cancer patients who have undergone mastectomy: A national cohort study.
    PLoS One. 2017;12:e0175395.
    PubMed     Text format     Abstract available


  76. GUO Y, Yu P, Liu Z, Maimaiti Y, et al
    Prognostic and clinicopathological value of GATA binding protein 3 in breast cancer: A systematic review and meta-analysis.
    PLoS One. 2017;12:e0174843.
    PubMed     Text format     Abstract available


  77. EL GUERRAB A, Cayre A, Kwiatkowski F, Privat M, et al
    Quantification of hypoxia-related gene expression as a potential approach for clinical outcome prediction in breast cancer.
    PLoS One. 2017;12:e0175960.
    PubMed     Text format     Abstract available


  78. TIRAN V, Stanzer S, Heitzer E, Meilinger M, et al
    Genetic profiling of putative breast cancer stem cells from malignant pleural effusions.
    PLoS One. 2017;12:e0175223.
    PubMed     Text format     Abstract available


  79. CASTLE J, Morris K, Pritchard S, Kirwan CC, et al
    Challenges in enumeration of CTCs in breast cancer using techniques independent of cytokeratin expression.
    PLoS One. 2017;12:e0175647.
    PubMed     Text format     Abstract available


  80. AHN SG, Lee JH, Lee HW, Jeon TJ, et al
    Comparison of standardized uptake value of 18F-FDG-PET-CT with 21-gene recurrence score in estrogen receptor-positive, HER2-negative breast cancer.
    PLoS One. 2017;12:e0175048.
    PubMed     Text format     Abstract available


  81. GRONBERG M, Ahlin C, Naeser Y, Janson ET, et al
    Ghrelin is a prognostic marker and a potential therapeutic target in breast cancer.
    PLoS One. 2017;12:e0176059.
    PubMed     Text format     Abstract available


  82. HADJIALIREZAEI S, Picco G, Beatson R, Burchell J, et al
    Interactions between the breast cancer-associated MUC1 mucins and C-type lectin characterized by optical tweezers.
    PLoS One. 2017;12:e0175323.
    PubMed     Text format     Abstract available


  83. BOYD A, Stoodley P, Richards D, Hui R, et al
    Anthracyclines induce early changes in left ventricular systolic and diastolic function: A single centre study.
    PLoS One. 2017;12:e0175544.
    PubMed     Text format     Abstract available


  84. MOHD MUJAR NM, Dahlui M, Emran NA, Abdul Hadi I, et al
    Complementary and alternative medicine (CAM) use and delays in presentation and diagnosis of breast cancer patients in public hospitals in Malaysia.
    PLoS One. 2017;12:e0176394.
    PubMed     Text format     Abstract available


  85. ALIMOHAMMADI M, Lahiani MH, McGehee D, Khodakovskaya M, et al
    Polyphenolic extract of InsP 5-ptase expressing tomato plants reduce the proliferation of MCF-7 breast cancer cells.
    PLoS One. 2017;12:e0175778.
    PubMed     Text format     Abstract available


  86. LU T, Gu M, Zhao Y, Zheng X, et al
    Autophagy contributes to falcarindiol-induced cell death in breast cancer cells with enhanced endoplasmic reticulum stress.
    PLoS One. 2017;12:e0176348.
    PubMed     Text format     Abstract available


  87. BAUER D, Redmon N, Mazzio E, Soliman KF, et al
    Apigenin inhibits TNFalpha/IL-1alpha-induced CCL2 release through IKBK-epsilon signaling in MDA-MB-231 human breast cancer cells.
    PLoS One. 2017;12:e0175558.
    PubMed     Text format     Abstract available


  88. ZHOU W, Song F, Wu Q, Liu R, et al
    miR-217 inhibits triple-negative breast cancer cell growth, migration, and invasion through targeting KLF5.
    PLoS One. 2017;12:e0176395.
    PubMed     Text format     Abstract available


  89. CHEN S, Tao J, Zhong F, Jiao Y, et al
    Polydatin down-regulates the phosphorylation level of Creb and induces apoptosis in human breast cancer cell.
    PLoS One. 2017;12:e0176501.
    PubMed     Text format     Abstract available


  90. GOODE G, Gunda V, Chaika NV, Purohit V, et al
    MUC1 facilitates metabolomic reprogramming in triple-negative breast cancer.
    PLoS One. 2017;12:e0176820.
    PubMed     Text format     Abstract available


  91. BARTEL CA, Jackson MW
    HER2-positive breast cancer cells expressing elevated FAM83A are sensitive to FAM83A loss.
    PLoS One. 2017;12:e0176778.
    PubMed     Text format     Abstract available


  92. PIO GM, Xia Y, Piaseczny MM, Chu JE, et al
    Soluble bone-derived osteopontin promotes migration and stem-like behavior of breast cancer cells.
    PLoS One. 2017;12:e0177640.
    PubMed     Text format     Abstract available


  93. CHANDA A, Chan A, Deng L, Kornaga EN, et al
    Identification of the SUMO E3 ligase PIAS1 as a potential survival biomarker in breast cancer.
    PLoS One. 2017;12:e0177639.
    PubMed     Text format     Abstract available


  94. COLLINS D, Jacob W, Cejalvo JM, Ceppi M, et al
    Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer.
    PLoS One. 2017;12:e0177331.
    PubMed     Text format     Abstract available


  95. TAKEUCHI H, Kawanaka H, Fukuyama S, Kubo N, et al
    Comparison of the prognostic values of preoperative inflammation-based parameters in patients with breast cancer.
    PLoS One. 2017;12:e0177137.
    PubMed     Text format     Abstract available


  96. KANOMATA N, Matsuura S, Nomura T, Kurebayashi J, et al
    Preparation of a novel antiserum to aromatase with high affinity and specificity: Its clinicopathological significance on breast cancer tissue.
    PLoS One. 2017;12:e0177439.
    PubMed     Text format     Abstract available


  97. SANTRA T, Roche S, Conlon N, O'Donovan N, et al
    Identification of potential new treatment response markers and therapeutic targets using a Gaussian process-based method in lapatinib insensitive breast cancer models.
    PLoS One. 2017;12:e0177058.
    PubMed     Text format     Abstract available


  98. HULTGREN EM, Patrick ME, Evans RL, Stoos CT, et al
    SUSD2 promotes tumor-associated macrophage recruitment by increasing levels of MCP-1 in breast cancer.
    PLoS One. 2017;12:e0177089.
    PubMed     Text format     Abstract available


  99. MARTINEZ ME, Unkart JT, Tao L, Kroenke CH, et al
    Prognostic significance of marital status in breast cancer survival: A population-based study.
    PLoS One. 2017;12:e0175515.
    PubMed     Text format     Abstract available


  100. MISHRA AK, Parish CR, Wong ML, Licinio J, et al
    Leptin signals via TGFB1 to promote metastatic potential and stemness in breast cancer.
    PLoS One. 2017;12:e0178454.
    PubMed     Text format     Abstract available


  101. EVERS C, Fischer C, Dikow N, Schott S, et al
    Familial breast cancer: Genetic counseling over time, including patients expectations and initiators considering the Angelina Jolie effect.
    PLoS One. 2017;12:e0177893.
    PubMed     Text format     Abstract available


  102. CHOI Y, Kim SH, Youn IK, Kang BJ, et al
    Rim sign and histogram analysis of apparent diffusion coefficient values on diffusion-weighted MRI in triple-negative breast cancer: Comparison with ER-positive subtype.
    PLoS One. 2017;12:e0177903.
    PubMed     Text format     Abstract available


  103. LIU Z, He K, Ma Q, Yu Q, et al
    Autophagy inhibitor facilitates gefitinib sensitivity in vitro and in vivo by activating mitochondrial apoptosis in triple negative breast cancer.
    PLoS One. 2017;12:e0177694.
    PubMed     Text format     Abstract available


  104. SCHMITZ AMT, Teixeira SC, Pengel KE, Loo CE, et al
    Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes.
    PLoS One. 2017;12:e0176782.
    PubMed     Text format     Abstract available


  105. WANG XY, Hu Q, Fang MY, He Y, et al
    The correlation between HER-2 expression and the CEUS and ARFI characteristics of breast cancer.
    PLoS One. 2017;12:e0178692.
    PubMed     Text format     Abstract available


  106. GOODE G, Gunda V, Chaika NV, Purohit V, et al
    Correction: MUC1 facilitates metabolomic reprogramming in triple-negative breast cancer.
    PLoS One. 2017;12:e0179098.
    PubMed     Text format     Abstract available


  107. ARAUJO T, Aresta G, Castro E, Rouco J, et al
    Classification of breast cancer histology images using Convolutional Neural Networks.
    PLoS One. 2017;12:e0177544.
    PubMed     Text format     Abstract available


  108. GWEON HM, Jeong J, Son EJ, Youk JH, et al
    The clinical significance of accompanying NME on preoperative MR imaging in breast cancer patients.
    PLoS One. 2017;12:e0178445.
    PubMed     Text format     Abstract available


  109. DE GROEF A, Van Kampen M, Vervloesem N, De Geyter S, et al
    An evaluation tool for myofascial adhesions in patients after breast cancer (MAP-BC evaluation tool): Development and interrater reliability.
    PLoS One. 2017;12:e0179116.
    PubMed     Text format     Abstract available


  110. GAMEZ-POZO A, Trilla-Fuertes L, Prado-Vazquez G, Chiva C, et al
    Prediction of adjuvant chemotherapy response in triple negative breast cancer with discovery and targeted proteomics.
    PLoS One. 2017;12:e0178296.
    PubMed     Text format     Abstract available


  111. ZHU RM, Lin W, Zhang W, Ren JT, et al
    Modification effects of genetic polymorphisms in FTO, IL-6, and HSPD1 on the associations of diabetes with breast cancer risk and survival.
    PLoS One. 2017;12:e0178850.
    PubMed     Text format     Abstract available


  112. JAEGER BAS, Neugebauer J, Andergassen U, Melcher C, et al
    The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial.
    PLoS One. 2017;12:e0173593.
    PubMed     Text format     Abstract available


  113. BORIN TF, Shankar A, Angara K, Rashid MH, et al
    HET0016 decreases lung metastasis from breast cancer in immune-competent mouse model.
    PLoS One. 2017;12:e0178830.
    PubMed     Text format     Abstract available


  114. TSAI YF, Tseng LM, Hsu CY, Yang MH, et al
    Brain-derived neurotrophic factor (BDNF) -TrKB signaling modulates cancer-endothelial cells interaction and affects the outcomes of triple negative breast cancer.
    PLoS One. 2017;12:e0178173.
    PubMed     Text format     Abstract available


  115. KIM HS, Tian L, Kim H, Moon WK, et al
    Investigation of discriminant metabolites in tamoxifen-resistant and choline kinase-alpha-downregulated breast cancer cells using 1H-nuclear magnetic resonance spectroscopy.
    PLoS One. 2017;12:e0179773.
    PubMed     Text format     Abstract available


  116. NAZIROGLU M, Cig B, Blum W, Vizler C, et al
    Targeting breast cancer cells by MRS1477, a positive allosteric modulator of TRPV1 channels.
    PLoS One. 2017;12:e0179950.
    PubMed     Text format     Abstract available


  117. BUEHRING GC, Shen H, Schwartz DA, Lawson JS, et al
    Bovine leukemia virus linked to breast cancer in Australian women and identified before breast cancer development.
    PLoS One. 2017;12:e0179367.
    PubMed     Text format     Abstract available


  118. LIU JC, Zacksenhouse M, Eisen A, Nofech-Mozes S, et al
    Identification of cell proliferation, immune response and cell migration as critical pathways in a prognostic signature for HER2+:ERalpha- breast cancer.
    PLoS One. 2017;12:e0179223.
    PubMed     Text format     Abstract available


  119. BJORGE JD, Pang A, Fujita DJ
    Delivery of gene targeting siRNAs to breast cancer cells using a multifunctional peptide complex that promotes both targeted delivery and endosomal release.
    PLoS One. 2017;12:e0180578.
    PubMed     Text format     Abstract available


  120. TAMURA M, Sugiura S, Takagi T, Satoh T, et al
    Morphology-based optical separation of subpopulations from a heterogeneous murine breast cancer cell line.
    PLoS One. 2017;12:e0179372.
    PubMed     Text format     Abstract available


  121. JEONG J, Park S, An HT, Kang M, et al
    Small leucine zipper protein functions as a negative regulator of estrogen receptor alpha in breast cancer.
    PLoS One. 2017;12:e0180197.
    PubMed     Text format     Abstract available


  122. AMARA S, Majors C, Roy B, Hill S, et al
    Critical role of SIK3 in mediating high salt and IL-17 synergy leading to breast cancer cell proliferation.
    PLoS One. 2017;12:e0180097.
    PubMed     Text format     Abstract available


  123. SKOOG P, Ohlsson M, Ferno M, Ryden L, et al
    Tumor tissue protein signatures reflect histological grade of breast cancer.
    PLoS One. 2017;12:e0179775.
    PubMed     Text format     Abstract available


  124. JI W, Wang B, Fan Q, Xu C, et al
    Chemosensitizing indomethacin-conjugated dextran-based micelles for effective delivery of paclitaxel in resistant breast cancer therapy.
    PLoS One. 2017;12:e0180037.
    PubMed     Text format     Abstract available


  125. CAO H, Li C, Qi W, Meng X, et al
    Synthesis, cytotoxicity and antitumour mechanism investigations of polyoxometalate doped silica nanospheres on breast cancer MCF-7 cells.
    PLoS One. 2017;12:e0181018.
    PubMed     Text format     Abstract available


  126. BALHOUSE BN, Patterson L, Schmelz EM, Slade DJ, et al
    N-(3-oxododecanoyl)-L-homoserine lactone interactions in the breast tumor microenvironment: Implications for breast cancer viability and proliferation in vitro.
    PLoS One. 2017;12:e0180372.
    PubMed     Text format     Abstract available


  127. PASCUAL T, Apellaniz-Ruiz M, Pernaut C, Cueto-Felgueroso C, et al
    Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer.
    PLoS One. 2017;12:e0180192.
    PubMed     Text format     Abstract available


  128. KONG W, Mou X, Deng J, Di B, et al
    Differences of immune disorders between Alzheimer's disease and breast cancer based on transcriptional regulation.
    PLoS One. 2017;12:e0180337.
    PubMed     Text format     Abstract available


  129. ABANA CO, Bingham BS, Cho JH, Graves AJ, et al
    IL-6 variant is associated with metastasis in breast cancer patients.
    PLoS One. 2017;12:e0181725.
    PubMed     Text format     Abstract available


  130. DONNELLY TT, Al-Khater AH, Al-Bader SB, Al-Kuwari MG, et al
    Perceptions of Arab men regarding female breast cancer screening examinations-Findings from a Middle East study.
    PLoS One. 2017;12:e0180696.
    PubMed     Text format     Abstract available


  131. SADIGHI S, Zokaasadi M, Kasaeian A, Maghsudi S, et al
    The effect of immunohistochemically detected p53 accumulation in prognosis of breast cancer; A retrospective survey of outcome.
    PLoS One. 2017;12:e0182444.
    PubMed     Text format     Abstract available


  132. ETTI IC, Abdullah R, Kadir A, Hashim NM, et al
    The molecular mechanism of the anticancer effect of Artonin E in MDA-MB 231 triple negative breast cancer cells.
    PLoS One. 2017;12:e0182357.
    PubMed     Text format     Abstract available


  133. SIM SH, Bae CD, Kwon Y, Hwang HL, et al
    CKAP2 (cytoskeleton-associated protein2) is a new prognostic marker in HER2-negative luminal type breast cancer.
    PLoS One. 2017;12:e0182107.
    PubMed     Text format     Abstract available


  134. MATOSSIAN MD, Elliott S, Hoang VT, Burks HE, et al
    Novel application of the published kinase inhibitor set to identify therapeutic targets and pathways in triple negative breast cancer subtypes.
    PLoS One. 2017;12:e0177802.
    PubMed     Text format     Abstract available


  135. CUBASCH H, Joffe M, Ruff P, Dietz D, et al
    Breast conservation surgery versus total mastectomy among women with localized breast cancer in Soweto, South Africa.
    PLoS One. 2017;12:e0182125.
    PubMed     Text format     Abstract available


  136. ZAGOURI F, Kotoula V, Kouvatseas G, Sotiropoulou M, et al
    Protein expression patterns of cell cycle regulators in operable breast cancer.
    PLoS One. 2017;12:e0180489.
    PubMed     Text format     Abstract available


  137. LEE S, Jiang X
    Modeling miRNA-mRNA interactions that cause phenotypic abnormality in breast cancer patients.
    PLoS One. 2017;12:e0182666.
    PubMed     Text format     Abstract available


  138. KANOMATA N, Matsuura S, Nomura T, Kurebayashi J, et al
    Correction: Preparation of a novel antiserum to aromatase with high affinity and specificity: Its clinicopathological significance on breast cancer tissue.
    PLoS One. 2017;12:e0183202.
    PubMed     Text format     Abstract available


  139. WANG RC, Chen X, Parissenti AM, Joy AA, et al
    Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.
    PLoS One. 2017;12:e0182400.
    PubMed     Text format     Abstract available


  140. PARK IA, Hwang SH, Song IH, Heo SH, et al
    Expression of the MHC class II in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and interferon signaling.
    PLoS One. 2017;12:e0182786.
    PubMed     Text format     Abstract available


  141. LI M, Chen K, Liu F, Su F, et al
    Nipple sparing mastectomy in breast cancer patients and long-term survival outcomes: An analysis of the SEER database.
    PLoS One. 2017;12:e0183448.
    PubMed     Text format     Abstract available


  142. HOSOKAWA Y, Masaki N, Takei S, Horikawa M, et al
    Recurrent triple-negative breast cancer (TNBC) tissues contain a higher amount of phosphatidylcholine (32:1) than non-recurrent TNBC tissues.
    PLoS One. 2017;12:e0183724.
    PubMed     Text format     Abstract available


  143. YTTERSIAN SLETTA K, Tveitaras MK, Lu N, Engelsen AST, et al
    Oxygen-dependent regulation of tumor growth and metastasis in human breast cancer xenografts.
    PLoS One. 2017;12:e0183254.
    PubMed     Text format     Abstract available


  144. WANG J, Kong X, Xing Z, Wang X, et al
    A meta-analysis: Is there any association between MiR-608 rs4919510 polymorphism and breast cancer risks?
    PLoS One. 2017;12:e0183012.
    PubMed     Text format     Abstract available


  145. CHIEN TJ, Hsu CH, Liu CY, Fang CJ, et al
    Effect of acupuncture on hot flush and menopause symptoms in breast cancer- A systematic review and meta-analysis.
    PLoS One. 2017;12:e0180918.
    PubMed     Text format     Abstract available


  146. MA S, Dielschneider RF, Henson ES, Xiao W, et al
    Ferroptosis and autophagy induced cell death occur independently after siramesine and lapatinib treatment in breast cancer cells.
    PLoS One. 2017;12:e0182921.
    PubMed     Text format     Abstract available


  147. CASTELLANO I, Metovic J, Balmativola D, Annaratone L, et al
    The impact of malignant nipple discharge cytology (NDc) in surgical management of breast cancer patients.
    PLoS One. 2017;12:e0182073.
    PubMed     Text format     Abstract available


  148. TANG C, Wang P, Li X, Zhao B, et al
    Lymph node status have a prognostic impact in breast cancer patients with distant metastasis.
    PLoS One. 2017;12:e0182953.
    PubMed     Text format     Abstract available


  149. MAHMOUD AM, Macias V, Al-Alem U, Deaton RJ, et al
    BRCA1 protein expression and subcellular localization in primary breast cancer: Automated digital microscopy analysis of tissue microarrays.
    PLoS One. 2017;12:e0184385.
    PubMed     Text format     Abstract available


  150. BOSL A, Spitzmuller A, Jasarevic Z, Rauch S, et al
    MammaPrint versus EndoPredict: Poor correlation in disease recurrence risk classification of hormone receptor positive breast cancer.
    PLoS One. 2017;12:e0183458.
    PubMed     Text format     Abstract available


  151. HANNA M, Dumas I, Orain M, Jacob S, et al
    Association between local inflammation and breast tissue age-related lobular involution among premenopausal and postmenopausal breast cancer patients.
    PLoS One. 2017;12:e0183579.
    PubMed     Text format     Abstract available


  152. WEN Y, Chen Z, Lu J, Ables E, et al
    Quantitative analysis and comparison of 3D morphology between viable and apoptotic MCF-7 breast cancer cells and characterization of nuclear fragmentation.
    PLoS One. 2017;12:e0184726.
    PubMed     Text format     Abstract available


  153. SCHULTZ DJ, Muluhngwi P, Alizadeh-Rad N, Green MA, et al
    Genome-wide miRNA response to anacardic acid in breast cancer cells.
    PLoS One. 2017;12:e0184471.
    PubMed     Text format     Abstract available


  154. CHENG SH, Huang TT, Cheng YH, Tan TBK, et al
    Validation of the 18-gene classifier as a prognostic biomarker of distant metastasis in breast cancer.
    PLoS One. 2017;12:e0184372.
    PubMed     Text format     Abstract available


  155. PELAEZ-GARCIA A, Yebenes L, Berjon A, Angulo A, et al
    Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancer.
    PLoS One. 2017;12:e0183452.
    PubMed     Text format     Abstract available


  156. CHANDLER MR, Keene KS, Tuomela JM, Forero-Torres A, et al
    Lower frequency of TLR9 variant associated with protection from breast cancer among African Americans.
    PLoS One. 2017;12:e0183832.
    PubMed     Text format     Abstract available


  157. KWIECIEN JM, Bassey-Archibong BI, Dabrowski W, Rayner LG, et al
    Loss of Kaiso expression in breast cancer cells prevents intra-vascular invasion in the lung and secondary metastasis.
    PLoS One. 2017;12:e0183883.
    PubMed     Text format     Abstract available


  158. ETTL J, Klein E, Hapfelmeier A, Grosse Lackmann K, et al
    Decision impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker uPA/PAI-1.
    PLoS One. 2017;12:e0183917.
    PubMed     Text format     Abstract available


  159. SU S, Bao H, Wang X, Wang Z, et al
    The quality of invasive breast cancer care for low reimbursement rate patients: A retrospective study.
    PLoS One. 2017;12:e0184866.
    PubMed     Text format     Abstract available


  160. ZEIDAN AM, Long JB, Wang R, Hu X, et al
    Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based study.
    PLoS One. 2017;12:e0184747.
    PubMed     Text format     Abstract available


  161. LEFTIN A, Ben-Chetrit N, Klemm F, Joyce JA, et al
    Iron imaging reveals tumor and metastasis macrophage hemosiderin deposits in breast cancer.
    PLoS One. 2017;12:e0184765.
    PubMed     Text format     Abstract available


  162. FUKADA I, Ito Y, Kobayashi K, Shibayama T, et al
    The early onset of peripheral neuropathy might be a robust predictor for time to treatment failure in patients with metastatic breast cancer receiving chemotherapy containing paclitaxel.
    PLoS One. 2017;12:e0184322.
    PubMed     Text format     Abstract available


  163. LU S, Qian Y, Huang X, Yu H, et al
    The association of dietary pattern and breast cancer in Jiangsu, China: A population-based case-control study.
    PLoS One. 2017;12:e0184453.
    PubMed     Text format     Abstract available


  164. POPOLIN CP, Reis JPB, Becceneri AB, Graminha AE, et al
    Cytotoxicity and anti-tumor effects of new ruthenium complexes on triple negative breast cancer cells.
    PLoS One. 2017;12:e0183275.
    PubMed     Text format     Abstract available


  165. GOTZ TI, Lahmer G, Strnad V, Bert C, et al
    A tool to automatically analyze electromagnetic tracking data from high dose rate brachytherapy of breast cancer patients.
    PLoS One. 2017;12:e0183608.
    PubMed     Text format     Abstract available


  166. PARK NJ, Chang Y, Bender C, Conley Y, et al
    Cardiovascular disease and mortality after breast cancer in postmenopausal women: Results from the Women's Health Initiative.
    PLoS One. 2017;12:e0184174.
    PubMed     Text format     Abstract available


  167. BUONOMO OC, Caredda E, Portarena I, Vanni G, et al
    New insights into the metastatic behavior after breast cancer surgery, according to well-established clinicopathological variables and molecular subtypes.
    PLoS One. 2017;12:e0184680.
    PubMed     Text format     Abstract available


  168. PADALA C, Tupurani MA, Puranam K, Gantala S, et al
    Synergistic effect of collagenase-1 (MMP1), stromelysin-1 (MMP3) and gelatinase-B (MMP9) gene polymorphisms in breast cancer.
    PLoS One. 2017;12:e0184448.
    PubMed     Text format     Abstract available


  169. FUJII T, Reuben JM, Huo L, Espinosa Fernandez JR, et al
    Androgen receptor expression on circulating tumor cells in metastatic breast cancer.
    PLoS One. 2017;12:e0185231.
    PubMed     Text format     Abstract available


  170. LAMPA M, Arlt H, He T, Ospina B, et al
    Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition.
    PLoS One. 2017;12:e0185092.
    PubMed     Text format     Abstract available


  171. SCHMITZ AMT, Veldhuis WB, Menke-Pluijmers MBE, van der Kemp WJM, et al
    Preoperative indication for systemic therapy extended to patients with early-stage breast cancer using multiparametric 7-tesla breast MRI.
    PLoS One. 2017;12:e0183855.
    PubMed     Text format     Abstract available


  172. GSCHWANTLER-KAULICH D, Weingartshofer S, Grunt TW, Mairhofer M, et al
    Estradiol impairs the antiproliferative and proapoptotic effect of Zoledronic acid in hormone sensitive breast cancer cells in vitro.
    PLoS One. 2017;12:e0185566.
    PubMed     Text format     Abstract available


  173. SUCHANSKI J, Tejchman A, Zacharski M, Piotrowska A, et al
    Podoplanin increases the migration of human fibroblasts and affects the endothelial cell network formation: A possible role for cancer-associated fibroblasts in breast cancer progression.
    PLoS One. 2017;12:e0184970.
    PubMed     Text format     Abstract available


  174. ZHANG W, Wang W, Chai W, Luo X, et al
    Breast tissue ablation with irreversible electroporation in rabbits: A safety and feasibility study.
    PLoS One. 2017;12:e0181555.
    PubMed     Text format     Abstract available


  175. DI NAPOLI A, Pepe G, Giarnieri E, Cippitelli C, et al
    Cytological diagnostic features of late breast implant seromas: From reactive to anaplastic large cell lymphoma.
    PLoS One. 2017;12:e0181097.
    PubMed     Text format     Abstract available


  176. SANO H, Goto R, Hamashima C
    Does lack of resources impair access to breast and cervical cancer screening in Japan?
    PLoS One. 2017;12:e0180819.
    PubMed     Text format     Abstract available


  177. KIRCHNER J, Sawicki LM, Deuschl C, Gruneisen J, et al
    18 F-FDG PET/MR imaging in patients with suspected liver lesions: Value of liver-specific contrast agent Gadobenate dimeglumine.
    PLoS One. 2017;12:e0180349.
    PubMed     Text format     Abstract available


  178. MARQUEZ-RODAS I, Pollan M, Escudero MJ, Ruiz A, et al
    Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM "El Alamo III" retrospective study.
    PLoS One. 2017;12:e0184181.
    PubMed     Text format     Abstract available


  179. CILEK EE, Ozturk H, Gur Dedeoglu B
    Construction of miRNA-miRNA networks revealing the complexity of miRNA-mediated mechanisms in trastuzumab treated breast cancer cell lines.
    PLoS One. 2017;12:e0185558.
    PubMed     Text format     Abstract available


  180. AUKES K, Forsman C, Brady NJ, Astleford K, et al
    Breast cancer cell-derived fibroblast growth factors enhance osteoclast activity and contribute to the formation of metastatic lesions.
    PLoS One. 2017;12:e0185736.
    PubMed     Text format     Abstract available


  181. KORKOLA JE, Collisson EA, Heiser LM, Oates C, et al
    Correction: Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer.
    PLoS One. 2017;12:e0186551.
    PubMed     Text format     Abstract available


  182. QIAO W, Jia Z, Liu H, Liu Q, et al
    Prognostic and clinicopathological value of Twist expression in breast cancer: A meta-analysis.
    PLoS One. 2017;12:e0186191.
    PubMed     Text format     Abstract available


  183. XIE F, Hosany S, Zhong S, Jiang Y, et al
    MicroRNA-193a inhibits breast cancer proliferation and metastasis by downregulating WT1.
    PLoS One. 2017;12:e0185565.
    PubMed     Text format     Abstract available


  184. THIRUNAVUKKARASAN M, Wang C, Rao A, Hind T, et al
    Short-chain fatty acid receptors inhibit invasive phenotypes in breast cancer cells.
    PLoS One. 2017;12:e0186334.
    PubMed     Text format     Abstract available


  185. MAHAJAN AS, Sugita BM, Duttargi AN, Saenz F, et al
    Genomic comparison of early-passage conditionally reprogrammed breast cancer cells to their corresponding primary tumors.
    PLoS One. 2017;12:e0186190.
    PubMed     Text format     Abstract available


  186. RAZAZAN A, Behravan J, Arab A, Barati N, et al
    Conjugated nanoliposome with the HER2/neu-derived peptide GP2 as an effective vaccine against breast cancer in mice xenograft model.
    PLoS One. 2017;12:e0185099.
    PubMed     Text format     Abstract available


  187. HEQUET D, Callens C, Gentien D, Albaud B, et al
    Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna(R) Test in the management of early-stage breast cancers.
    PLoS One. 2017;12:e0185753.
    PubMed     Text format     Abstract available


  188. PEARCE A, Haas M, Viney R, Pearson SA, et al
    Incidence and severity of self-reported chemotherapy side effects in routine care: A prospective cohort study.
    PLoS One. 2017;12:e0184360.
    PubMed     Text format     Abstract available


  189. VALIANATOS G, Valcikova B, Growkova K, Verlande A, et al
    A small molecule drug promoting miRNA processing induces alternative splicing of MdmX transcript and rescues p53 activity in human cancer cells overexpressing MdmX protein.
    PLoS One. 2017;12:e0185801.
    PubMed     Text format     Abstract available


  190. HEBBRECHT T, Van Audenhove I, Zwaenepoel O, Verhelle A, et al
    VCA nanobodies target N-WASp to reduce invadopodium formation and functioning.
    PLoS One. 2017;12:e0185076.
    PubMed     Text format     Abstract available


  191. NISHIMUKAI A, Inoue N, Kira A, Takeda M, et al
    Tumor size and proliferative marker geminin rather than Ki67 expression levels significantly associated with maximum uptake of 18F-deoxyglucose levels on positron emission tomography for breast cancers.
    PLoS One. 2017;12:e0184508.
    PubMed     Text format     Abstract available


  192. SERRANO-GOMEZ SJ, Sanabria-Salas MC, Garay J, Baddoo MC, et al
    Ancestry as a potential modifier of gene expression in breast tumors from Colombian women.
    PLoS One. 2017;12:e0183179.
    PubMed     Text format     Abstract available


  193. DIMITROPOULOS K, Barmpoutis P, Zioga C, Kamas A, et al
    Grading of invasive breast carcinoma through Grassmannian VLAD encoding.
    PLoS One. 2017;12:e0185110.
    PubMed     Text format     Abstract available


  194. KANG HJ, Kim SW, Son SH
    The feasibility of a heart block with an electron compensation as an alternative whole breast radiotherapy technique in patients with underlying cardiac or pulmonary disease.
    PLoS One. 2017;12:e0184137.
    PubMed     Text format     Abstract available


  195. CHEN Z, Yang J, Li S, Lv M, et al
    Invasive lobular carcinoma of the breast: A special histological type compared with invasive ductal carcinoma.
    PLoS One. 2017;12:e0182397.
    PubMed     Text format     Abstract available


  196. PARK JM, Bae SJ, Yoon C, Lee HS, et al
    Comparison of patients with small (</=2 cm) breast cancer according to adherence to breast screening program.
    PLoS One. 2017;12:e0186988.
    PubMed     Text format     Abstract available


  197. LAI HW, Liu LC, Ouyang F, Yao CC, et al
    Multi-center study on patient selection for and the oncologic safety of intraoperative radiotherapy (IORT) with the Xoft Axxent(R) eBx(R) System for the management of early stage breast cancer in Taiwan.
    PLoS One. 2017;12:e0185876.
    PubMed     Text format     Abstract available


  198. HENLE AM, Nassar A, Puglisi-Knutson D, Youssef B, et al
    Downregulation of TAP1 and TAP2 in early stage breast cancer.
    PLoS One. 2017;12:e0187323.
    PubMed     Text format     Abstract available


  199. COIGNET MV, Zirpoli GR, Roberts MR, Khoury T, et al
    Genetic variations, reproductive aging, and breast cancer risk in African American and European American women: The Women's Circle of Health Study.
    PLoS One. 2017;12:e0187205.
    PubMed     Text format     Abstract available


  200. JOHANNESSEN C, Moi L, Kiselev Y, Pedersen MI, et al
    Expression and function of the miR-143/145 cluster in vitro and in vivo in human breast cancer.
    PLoS One. 2017;12:e0186658.
    PubMed     Text format     Abstract available


  201. REESE DE, Henderson MC, Silver M, Mulpuri R, et al
    Breast density does not impact the ability of Videssa(R) Breast to detect breast cancer in women under age 50.
    PLoS One. 2017;12:e0186198.
    PubMed     Text format     Abstract available


  202. SUNG PL, Wen KC, Chen YJ, Chao TC, et al
    The frequency of cancer predisposition gene mutations in hereditary breast and ovarian cancer patients in Taiwan: From BRCA1/2 to multi-gene panels.
    PLoS One. 2017;12:e0185615.
    PubMed     Text format     Abstract available


  203. LAROCHE F, Perrot S, Medkour T, Cottu PH, et al
    Quality of life and impact of pain in women treated with aromatase inhibitors for breast cancer. A multicenter cohort study.
    PLoS One. 2017;12:e0187165.
    PubMed     Text format     Abstract available


  204. WAKAI R, Ishitsuka M, Kishimoto T, Ochiai T, et al
    Identification of genes and critical control proteins associated with inflammatory breast cancer using network controllability.
    PLoS One. 2017;12:e0186353.
    PubMed     Text format     Abstract available


  205. THERIAU CF, Sauve OS, Beaudoin MS, Wright DC, et al
    Proliferative endocrine effects of adipose tissue from obese animals on MCF7 cells are ameliorated by resveratrol supplementation.
    PLoS One. 2017;12:e0183897.
    PubMed     Text format     Abstract available


    January 2016
  206. BALAJI SA, Udupa N, Chamallamudi MR, Gupta V, et al
    Role of the Drug Transporter ABCC3 in Breast Cancer Chemoresistance.
    PLoS One. 2016;11:e0155013.
    PubMed     Text format     Abstract available


  207. APRELIKOVA O, Tomlinson CC, Hoenerhoff M, Hixon JA, et al
    Development and Preclinical Application of an Immunocompetent Transplant Model of Basal Breast Cancer with Lung, Liver and Brain Metastases.
    PLoS One. 2016;11:e0155262.
    PubMed     Text format     Abstract available


  208. KALA R, Tollefsbol TO
    A Novel Combinatorial Epigenetic Therapy Using Resveratrol and Pterostilbene for Restoring Estrogen Receptor-alpha (ERalpha) Expression in ERalpha-Negative Breast Cancer Cells.
    PLoS One. 2016;11:e0155057.
    PubMed     Text format     Abstract available


  209. YANG J, Niu H, Huang Y, Yang K, et al
    A Systematic Analysis of the Relationship of CDH13 Promoter Methylation and Breast Cancer Risk and Prognosis.
    PLoS One. 2016;11:e0149185.
    PubMed     Text format     Abstract available


  210. BASTOS EP, Brentani H, Pereira CA, Polpo A, et al
    A Set of miRNAs, Their Gene and Protein Targets and Stromal Genes Distinguish Early from Late Onset ER Positive Breast Cancer.
    PLoS One. 2016;11:e0154325.
    PubMed     Text format     Abstract available


  211. WON HS, Lee KM, Oh JE, Nam EM, et al
    Inhibition of beta-Catenin to Overcome Endocrine Resistance in Tamoxifen-Resistant Breast Cancer Cell Line.
    PLoS One. 2016;11:e0155983.
    PubMed     Text format     Abstract available


  212. LEI L, Yu X, Chen B, Chen Z, et al
    Clinicopathological Characteristics of Mucinous Breast Cancer: A Retrospective Analysis of a 10-Year Study.
    PLoS One. 2016;11:e0155132.
    PubMed     Text format     Abstract available


  213. HIGUCHI T, Endo M, Hanamura T, Gohno T, et al
    Contribution of Estrone Sulfate to Cell Proliferation in Aromatase Inhibitor (AI) -Resistant, Hormone Receptor-Positive Breast Cancer.
    PLoS One. 2016;11:e0155844.
    PubMed     Text format     Abstract available


  214. GUO Y, Yu P, Liu Z, Maimaiti Y, et al
    Prognostic and Clinicopathological Value of Programmed Death Ligand-1 in Breast Cancer: A Meta-Analysis.
    PLoS One. 2016;11:e0156323.
    PubMed     Text format     Abstract available


  215. GORI S, Inno A, Rossi V, Turazza M, et al
    Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study.
    PLoS One. 2016;11:e0156221.
    PubMed     Text format     Abstract available


  216. SOPRANO M, Sorriento D, Rusciano MR, Maione AS, et al
    Oxidative Stress Mediates the Antiproliferative Effects of Nelfinavir in Breast Cancer Cells.
    PLoS One. 2016;11:e0155970.
    PubMed     Text format     Abstract available


  217. ZHANG X, Li Y, Zhou Y, Mao F, et al
    Diagnostic Performance of Indocyanine Green-Guided Sentinel Lymph Node Biopsy in Breast Cancer: A Meta-Analysis.
    PLoS One. 2016;11:e0155597.
    PubMed     Text format     Abstract available


  218. CHEREAU E, Uzan C, Boutmy-Deslandes E, Zohar S, et al
    Evaluation of the Effects of Pasireotide LAR Administration on Lymphocele Prevention after Axillary Node Dissection for Breast Cancer: Results of a Randomized Non-Comparative Phase 2 Study.
    PLoS One. 2016;11:e0156096.
    PubMed     Text format     Abstract available


  219. RENAULT AL, Lesueur F, Coulombe Y, Gobeil S, et al
    ABRAXAS (FAM175A) and Breast Cancer Susceptibility: No Evidence of Association in the Breast Cancer Family Registry.
    PLoS One. 2016;11:e0156820.
    PubMed     Text format     Abstract available


  220. ZHONG X, Dong Z, Dong H, Li J, et al
    Prevalence and Prognostic Role of BRCA1/2 Variants in Unselected Chinese Breast Cancer Patients.
    PLoS One. 2016;11:e0156789.
    PubMed     Text format     Abstract available


  221. LEHMANN BD, Jovanovic B, Chen X, Estrada MV, et al
    Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.
    PLoS One. 2016;11:e0157368.
    PubMed     Text format     Abstract available


  222. CUSTODIO ID, Marinho ED, Gontijo CA, Pereira TS, et al
    Impact of Chemotherapy on Diet and Nutritional Status of Women with Breast Cancer: A Prospective Study.
    PLoS One. 2016;11:e0157113.
    PubMed     Text format     Abstract available


  223. GUEST SK, Ribas R, Pancholi S, Nikitorowicz-Buniak J, et al
    Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
    PLoS One. 2016;11:e0157397.
    PubMed     Text format     Abstract available


  224. ROBERTS GC, Morris PG, Moss MA, Maltby SL, et al
    An Evaluation of Matrix-Containing and Humanised Matrix-Free 3-Dimensional Cell Culture Systems for Studying Breast Cancer.
    PLoS One. 2016;11:e0157004.
    PubMed     Text format     Abstract available


  225. LI Y, Wu Q, Li C, Liu L, et al
    Role of Human Breast Cancer Related Protein versus P-Glycoprotein as an Efflux Transporter for Benzylpenicillin: Potential Importance at the Blood-Brain Barrier.
    PLoS One. 2016;11:e0157576.
    PubMed     Text format     Abstract available


  226. LI J, Liu Y, Jiang Y, Shao Z, et al
    Breast Cancer-Specific Mortality Pattern and Its Changing Feature According to Estrogen Receptor Status in Two Time Periods.
    PLoS One. 2016;11:e0157322.
    PubMed     Text format     Abstract available


  227. WULANINGSIH W, Holmberg L, Abeler-Doner L, Ng T, et al
    Associations of C-Reactive Protein, Granulocytes and Granulocyte-to-Lymphocyte Ratio with Mortality from Breast Cancer in Non-Institutionalized American Women.
    PLoS One. 2016;11:e0157482.
    PubMed     Text format     Abstract available


  228. RIVERA RIVERA A, Castillo-Pichardo L, Gerena Y, Dharmawardhane S, et al
    Anti-Breast Cancer Potential of Quercetin via the Akt/AMPK/Mammalian Target of Rapamycin (mTOR) Signaling Cascade.
    PLoS One. 2016;11:e0157251.
    PubMed     Text format     Abstract available


  229. ZHOU Y, Wang C, Zhu H, Lin Y, et al
    Diagnostic Accuracy of PIK3CA Mutation Detection by Circulating Free DNA in Breast Cancer: A Meta-Analysis of Diagnostic Test Accuracy.
    PLoS One. 2016;11:e0158143.
    PubMed     Text format     Abstract available


  230. TANG Z, Wang J, Zhang H, Sun L, et al
    Associations between Diabetes and Quality of Life among Breast Cancer Survivors.
    PLoS One. 2016;11:e0157791.
    PubMed     Text format     Abstract available


  231. VALLEGA KA, Liu N, Myers JS, Yu K, et al
    Elevated Resistin Gene Expression in African American Estrogen and Progesterone Receptor Negative Breast Cancer.
    PLoS One. 2016;11:e0157741.
    PubMed     Text format     Abstract available


  232. PAEZ-RIBES M, Man S, Xu P, Kerbel RS, et al
    Development of Patient Derived Xenograft Models of Overt Spontaneous Breast Cancer Metastasis: A Cautionary Note.
    PLoS One. 2016;11:e0158034.
    PubMed     Text format     Abstract available


  233. ZIEGLER YS, Moresco JJ, Yates JR 3rd, Nardulli AM, et al
    Integration of Breast Cancer Secretomes with Clinical Data Elucidates Potential Serum Markers for Disease Detection, Diagnosis, and Prognosis.
    PLoS One. 2016;11:e0158296.
    PubMed     Text format     Abstract available


  234. MEDINA-AGUILAR R, Perez-Plasencia C, Marchat LA, Gariglio P, et al
    Methylation Landscape of Human Breast Cancer Cells in Response to Dietary Compound Resveratrol.
    PLoS One. 2016;11:e0157866.
    PubMed     Text format     Abstract available


  235. DORLING L, Kar S, Michailidou K, Hiller L, et al
    The Relationship between Common Genetic Markers of Breast Cancer Risk and Chemotherapy-Induced Toxicity: A Case-Control Study.
    PLoS One. 2016;11:e0158984.
    PubMed     Text format     Abstract available


  236. DIAS JA, Fredrikson GN, Ericson U, Gullberg B, et al
    Low-Grade Inflammation, Oxidative Stress and Risk of Invasive Post-Menopausal Breast Cancer - A Nested Case-Control Study from the Malmo Diet and Cancer Cohort.
    PLoS One. 2016;11:e0158959.
    PubMed     Text format     Abstract available


  237. KOO HY, Seo YG, Cho MH, Kim MJ, et al
    Weight Change and Associated Factors in Long-Term Breast Cancer Survivors.
    PLoS One. 2016;11:e0159098.
    PubMed     Text format     Abstract available


  238. HU K, Lou L, Tian W, Pan T, et al
    The Outcome of Breast Cancer Is Associated with National Human Development Index and Health System Attainment.
    PLoS One. 2016;11:e0158951.
    PubMed     Text format     Abstract available


  239. SINGH B, Kinne HE, Milligan RD, Washburn LJ, et al
    Important Role of FTO in the Survival of Rare Panresistant Triple-Negative Inflammatory Breast Cancer Cells Facing a Severe Metabolic Challenge.
    PLoS One. 2016;11:e0159072.
    PubMed     Text format     Abstract available


  240. VALLERAND D, Massonnet G, Kebir F, Gentien D, et al
    Characterization of Breast Cancer Preclinical Models Reveals a Specific Pattern of Macrophage Polarization.
    PLoS One. 2016;11:e0157670.
    PubMed     Text format     Abstract available


  241. BONSANG-KITZIS H, Chaltier L, Belin L, Savignoni A, et al
    Correction: Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.
    PLoS One. 2016;11:e0159123.
    PubMed     Text format     Abstract available


  242. CHOI HY, Ko ES, Han BK, Kim EJ, et al
    Prognostic Significance of Transverse Relaxation Rate (R2*) in Blood Oxygenation Level-Dependent Magnetic Resonance Imaging in Patients with Invasive Breast Cancer.
    PLoS One. 2016;11:e0158500.
    PubMed     Text format     Abstract available


  243. BENNANI-BAITI B, Dietzel M, Baltzer PA
    MRI Background Parenchymal Enhancement Is Not Associated with Breast Cancer.
    PLoS One. 2016;11:e0158573.
    PubMed     Text format     Abstract available


  244. CARRIER M, Joint M, Lutzing R, Page A, et al
    Phosphoproteome and Transcriptome of RA-Responsive and RA-Resistant Breast Cancer Cell Lines.
    PLoS One. 2016;11:e0157290.
    PubMed     Text format     Abstract available


  245. CHAE EY, Moon WK, Kim HH, Kim WH, et al
    Association between Ultrasound Features and the 21-Gene Recurrence Score Assays in Patients with Oestrogen Receptor-Positive, HER2-Negative, Invasive Breast Cancer.
    PLoS One. 2016;11:e0158461.
    PubMed     Text format     Abstract available


  246. MA Y, Yin F, Zhang T, Zhou XA, et al
    Selection of the Maximum Spatial Cluster Size of the Spatial Scan Statistic by Using the Maximum Clustering Set-Proportion Statistic.
    PLoS One. 2016;11:e0147918.
    PubMed     Text format     Abstract available


  247. GOGOI P, Sepehri S, Zhou Y, Gorin MA, et al
    Development of an Automated and Sensitive Microfluidic Device for Capturing and Characterizing Circulating Tumor Cells (CTCs) from Clinical Blood Samples.
    PLoS One. 2016;11:e0147400.
    PubMed     Text format     Abstract available


  248. MARVIBAIGI M, Amini N, Supriyanto E, Abdul Majid FA, et al
    Antioxidant Activity and ROS-Dependent Apoptotic Effect of Scurrula ferruginea (Jack) Danser Methanol Extract in Human Breast Cancer Cell MDA-MB-231.
    PLoS One. 2016;11:e0158942.
    PubMed     Text format     Abstract available


  249. YU C, Wang J
    A Physical Mechanism and Global Quantification of Breast Cancer.
    PLoS One. 2016;11:e0157422.
    PubMed     Text format     Abstract available


  250. THAKUR S, Grover RK, Gupta S, Yadav AK, et al
    Identification of Specific miRNA Signature in Paired Sera and Tissue Samples of Indian Women with Triple Negative Breast Cancer.
    PLoS One. 2016;11:e0158946.
    PubMed     Text format     Abstract available


  251. KLOTEN V, Schlensog M, Eschenbruch J, Gasthaus J, et al
    Abundant NDRG2 Expression Is Associated with Aggressiveness and Unfavorable Patients' Outcome in Basal-Like Breast Cancer.
    PLoS One. 2016;11:e0159073.
    PubMed     Text format     Abstract available


  252. BAUR B, Bozdag S
    A Feature Selection Algorithm to Compute Gene Centric Methylation from Probe Level Methylation Data.
    PLoS One. 2016;11:e0148977.
    PubMed     Text format     Abstract available


  253. DEVLIN KL, Sanford T, Harrison LM, LeBourgeois P, et al
    Stage-Specific MicroRNAs and Their Role in the Anticancer Effects of Calorie Restriction in a Rat Model of ER-Positive Luminal Breast Cancer.
    PLoS One. 2016;11:e0159686.
    PubMed     Text format     Abstract available


  254. QIU J, Guan J, Yang X, Wu J, et al
    Quality of Life and Psychological State in Chinese Breast Cancer Patients Who Received BRCA1/2 Genetic Testing.
    PLoS One. 2016;11:e0158531.
    PubMed     Text format     Abstract available


  255. PEREZ-PEREZ A, Sanchez-Jimenez F, Vilarino-Garcia T, de la Cruz L, et al
    Sam68 Mediates the Activation of Insulin and Leptin Signalling in Breast Cancer Cells.
    PLoS One. 2016;11:e0158218.
    PubMed     Text format     Abstract available


  256. ONER C, Turgut Cosan D, Colak E
    Estrogen and Androgen Hormone Levels Modulate the Expression of PIWI Interacting RNA in Prostate and Breast Cancer.
    PLoS One. 2016;11:e0159044.
    PubMed     Text format     Abstract available


  257. TAVAKOLI TABA S, Hossain L, Heard R, Brennan P, et al
    Personal and Network Dynamics in Performance of Knowledge Workers: A Study of Australian Breast Radiologists.
    PLoS One. 2016;11:e0150186.
    PubMed     Text format     Abstract available


  258. MU WJ, Zhong WJ, Yao JY, Li LJ, et al
    Ultrasonic Elastography Research Based on a Multicenter Study: Adding Strain Ratio after 5-Point Scoring Evaluation or Not.
    PLoS One. 2016;11:e0148330.
    PubMed     Text format     Abstract available


  259. ASANO Y, Kashiwagi S, Onoda N, Noda S, et al
    Platelet-Lymphocyte Ratio as a Useful Predictor of the Therapeutic Effect of Neoadjuvant Chemotherapy in Breast Cancer.
    PLoS One. 2016;11:e0153459.
    PubMed     Text format     Abstract available


  260. HE S, Wang M, Yang Z, Zhang J, et al
    Comparison of 18F-FES, 18F-FDG, and 18F-FMISO PET Imaging Probes for Early Prediction and Monitoring of Response to Endocrine Therapy in a Mouse Xenograft Model of ER-Positive Breast Cancer.
    PLoS One. 2016;11:e0159916.
    PubMed     Text format     Abstract available


  261. LORSY E, Topuz AS, Geisler C, Stahl S, et al
    Loss of Dickkopf 3 Promotes the Tumorigenesis of Basal Breast Cancer.
    PLoS One. 2016;11:e0160077.
    PubMed     Text format     Abstract available


  262. STOCKER A, Hilbers ML, Gauthier C, Grogg J, et al
    HER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy.
    PLoS One. 2016;11:e0159176.
    PubMed     Text format     Abstract available


  263. CHEN J, Yang C, Guo B, Sena ES, et al
    The Efficacy of Trastuzumab in Animal Models of Breast Cancer: A Systematic Review and Meta-Analysis.
    PLoS One. 2016;11:e0158240.
    PubMed     Text format     Abstract available


  264. RIBE AR, Laurberg T, Laursen TM, Charles M, et al
    Ten-Year Mortality after a Breast Cancer Diagnosis in Women with Severe Mental Illness: A Danish Population-Based Cohort Study.
    PLoS One. 2016;11:e0158013.
    PubMed     Text format     Abstract available


  265. POSSO M, Carles M, Rue M, Puig T, et al
    Cost-Effectiveness of Double Reading versus Single Reading of Mammograms in a Breast Cancer Screening Programme.
    PLoS One. 2016;11:e0159806.
    PubMed     Text format     Abstract available


  266. YOON H, Yoon D, Yun M, Choi JS, et al
    Metabolomics of Breast Cancer Using High-Resolution Magic Angle Spinning Magnetic Resonance Spectroscopy: Correlations with 18F-FDG Positron Emission Tomography-Computed Tomography, Dynamic Contrast-Enhanced and Diffusion-Weighted Imaging MRI.
    PLoS One. 2016;11:e0159949.
    PubMed     Text format     Abstract available


  267. IGNATIADIS M, Zardavas D, Lemort M, Wilke C, et al
    Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer.
    PLoS One. 2016;11:e0154009.
    PubMed     Text format     Abstract available


  268. TODOROVA VK, Makhoul I, Siegel ER, Wei J, et al
    Biomarkers for Presymptomatic Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients.
    PLoS One. 2016;11:e0160224.
    PubMed     Text format     Abstract available


  269. LINHER-MELVILLE K, Nashed MG, Ungard RG, Haftchenary S, et al
    Chronic Inhibition of STAT3/STAT5 in Treatment-Resistant Human Breast Cancer Cell Subtypes: Convergence on the ROS/SUMO Pathway and Its Effects on xCT Expression and System xc- Activity.
    PLoS One. 2016;11:e0161202.
    PubMed     Text format     Abstract available


  270. WULANINGSIH W, Holmberg L, Abeler-Dorner L, Ng T, et al
    Correction: Associations of C-Reactive Protein, Granulocytes and Granulocyte-to-Lymphocyte Ratio with Mortality from Breast Cancer in Non-Institutionalized American Women.
    PLoS One. 2016;11:e0161418.
    PubMed     Text format     Abstract available


  271. HENDERSON MC, Hollingsworth AB, Gordon K, Silver M, et al
    Integration of Serum Protein Biomarker and Tumor Associated Autoantibody Expression Data Increases the Ability of a Blood-Based Proteomic Assay to Identify Breast Cancer.
    PLoS One. 2016;11:e0157692.
    PubMed     Text format     Abstract available


  272. GOMEZ-ACEBO I, Dierssen-Sotos T, Palazuelos C, Perez-Gomez B, et al
    The Use of Antihypertensive Medication and the Risk of Breast Cancer in a Case-Control Study in a Spanish Population: The MCC-Spain Study.
    PLoS One. 2016;11:e0159672.
    PubMed     Text format     Abstract available


  273. CHEN X, Zhong SL, Lu P, Wang DD, et al
    miR-4443 Participates in the Malignancy of Breast Cancer.
    PLoS One. 2016;11:e0160780.
    PubMed     Text format     Abstract available


  274. LEDGER AE, Scurr ED, Hughes J, Macdonald A, et al
    Comparison of Dixon Sequences for Estimation of Percent Breast Fibroglandular Tissue.
    PLoS One. 2016;11:e0152152.
    PubMed     Text format     Abstract available


  275. KATAYAMA K, Narimatsu H
    Prediction of Female Breast Cancer Incidence among the Aging Society in Kanagawa, Japan.
    PLoS One. 2016;11:e0159913.
    PubMed     Text format     Abstract available


  276. FANI S, Dehghan F, Karimian H, Mun Lo K, et al
    Monobenzyltin Complex C1 Induces Apoptosis in MCF-7 Breast Cancer Cells through the Intrinsic Signaling Pathway and through the Targeting of MCF-7-Derived Breast Cancer Stem Cells via the Wnt/beta-Catenin Signaling Pathway.
    PLoS One. 2016;11:e0160836.
    PubMed     Text format     Abstract available


  277. VETA M, van Diest PJ, Jiwa M, Al-Janabi S, et al
    Mitosis Counting in Breast Cancer: Object-Level Interobserver Agreement and Comparison to an Automatic Method.
    PLoS One. 2016;11:e0161286.
    PubMed     Text format     Abstract available


  278. XU T, Le TD, Liu L, Wang R, et al
    Identifying Cancer Subtypes from miRNA-TF-mRNA Regulatory Networks and Expression Data.
    PLoS One. 2016;11:e0152792.
    PubMed     Text format     Abstract available


  279. TELLAROLI P, Bazzi M, Donato M, Brazzale AR, et al
    Cross-Clustering: A Partial Clustering Algorithm with Automatic Estimation of the Number of Clusters.
    PLoS One. 2016;11:e0152333.
    PubMed     Text format     Abstract available


  280. KROIGARD AB, Thomassen M, Laenkholm AV, Kruse TA, et al
    Evaluation of Nine Somatic Variant Callers for Detection of Somatic Mutations in Exome and Targeted Deep Sequencing Data.
    PLoS One. 2016;11:e0151664.
    PubMed     Text format     Abstract available


  281. NYBAKKEN GE, Bala R, Gratzinger D, Jones CD, et al
    Isolated Follicles Enriched for Centroblasts and Lacking t(14;18)/BCL2 in Lymphoid Tissue: Diagnostic and Clinical Implications.
    PLoS One. 2016;11:e0151735.
    PubMed     Text format     Abstract available


  282. GUTNIK L, Moses A, Stanley C, Tembo T, et al
    From Community Laywomen to Breast Health Workers: A Pilot Training Model to Implement Clinical Breast Exam Screening in Malawi.
    PLoS One. 2016;11:e0151389.
    PubMed     Text format     Abstract available


  283. KIM HS, Park S, Koo JS, Kim S, et al
    Risk Factors Associated with Discordant Ki-67 Levels between Preoperative Biopsy and Postoperative Surgical Specimens in Breast Cancers.
    PLoS One. 2016;11:e0151054.
    PubMed     Text format     Abstract available


  284. SHERMAN ME, Ichikawa L, Pfeiffer RM, Miglioretti DL, et al
    Relationship of Predicted Risk of Developing Invasive Breast Cancer, as Assessed with Three Models, and Breast Cancer Mortality among Breast Cancer Patients.
    PLoS One. 2016;11:e0160966.
    PubMed     Text format     Abstract available


  285. HORNE HN, Chung CC, Zhang H, Yu K, et al
    Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus.
    PLoS One. 2016;11:e0160316.
    PubMed     Text format     Abstract available


  286. LIU J, Sieuwerts AM, Look MP, van der Vlugt-Daane M, et al
    The 29.5 kb APOBEC3B Deletion Polymorphism Is Not Associated with Clinical Outcome of Breast Cancer.
    PLoS One. 2016;11:e0161731.
    PubMed     Text format     Abstract available


  287. SILVA VL, Ferreira D, Nobrega FL, Martins IM, et al
    Selection of Novel Peptides Homing the 4T1 CELL Line: Exploring Alternative Targets for Triple Negative Breast Cancer.
    PLoS One. 2016;11:e0161290.
    PubMed     Text format     Abstract available


  288. MILLS D, Gomberawalla A, Gordon EJ, Tondre J, et al
    Examination of Duct Physiology in the Human Mammary Gland.
    PLoS One. 2016;11:e0150653.
    PubMed     Text format     Abstract available


  289. ZHANG W, Le TD, Liu L, Zhou ZH, et al
    Predicting miRNA Targets by Integrating Gene Regulatory Knowledge with Expression Profiles.
    PLoS One. 2016;11:e0152860.
    PubMed     Text format     Abstract available


  290. MOREL V, Joly D, Villatte C, Dubray C, et al
    Memantine before Mastectomy Prevents Post-Surgery Pain: A Randomized, Blinded Clinical Trial in Surgical Patients.
    PLoS One. 2016;11:e0152741.
    PubMed     Text format     Abstract available


  291. FISKAA T, Knutsen E, Nikolaisen MA, Jorgensen TE, et al
    Distinct Small RNA Signatures in Extracellular Vesicles Derived from Breast Cancer Cell Lines.
    PLoS One. 2016;11:e0161824.
    PubMed     Text format     Abstract available


  292. MA X, Wang X, Huang J, Chen Y, et al
    Bevacizumab Addition in Neoadjuvant Treatment Increases the Pathological Complete Response Rates in Patients with HER-2 Negative Breast Cancer Especially Triple Negative Breast Cancer: A Meta-Analysis.
    PLoS One. 2016;11:e0160148.
    PubMed     Text format     Abstract available


  293. ENNOUR-IDRISSI K, Tetu B, Maunsell E, Poirier B, et al
    Association of Telomere Length with Breast Cancer Prognostic Factors.
    PLoS One. 2016;11:e0161903.
    PubMed     Text format     Abstract available


  294. NORTON N, Advani PP, Serie DJ, Geiger XJ, et al
    Assessment of Tumor Heterogeneity, as Evidenced by Gene Expression Profiles, Pathway Activation, and Gene Copy Number, in Patients with Multifocal Invasive Lobular Breast Tumors.
    PLoS One. 2016;11:e0153411.
    PubMed     Text format     Abstract available


  295. YANG SN, Li FJ, Chen JM, Zhang G, et al
    Kinetic Curve Type Assessment for Classification of Breast Lesions Using Dynamic Contrast-Enhanced MR Imaging.
    PLoS One. 2016;11:e0152827.
    PubMed     Text format     Abstract available


  296. CHAPA J, An G, Kulkarni SA
    Examining the Relationship between Pre-Malignant Breast Lesions, Carcinogenesis and Tumor Evolution in the Mammary Epithelium Using an Agent-Based Model.
    PLoS One. 2016;11:e0152298.
    PubMed     Text format     Abstract available


  297. BENNANI-BAITI B, Dietzel M, Baltzer PA
    Correction: MRI Background Parenchymal Enhancement Is Not Associated with Breast Cancer.
    PLoS One. 2016;11:e0162936.
    PubMed     Text format     Abstract available


  298. GENG C, Chen X, Pan X, Li J, et al
    The Feasibility and Accuracy of Sentinel Lymph Node Biopsy in Initially Clinically Node-Negative Breast Cancer after Neoadjuvant Chemotherapy: A Systematic Review and Meta-Analysis.
    PLoS One. 2016;11:e0162605.
    PubMed     Text format     Abstract available


  299. KIM HS, Jung M, Choi SK, Moon WK, et al
    Different Biological Action of Oleic Acid in ALDHhigh and ALDHlow Subpopulations Separated from Ductal Carcinoma In Situ of Breast Cancer.
    PLoS One. 2016;11:e0160835.
    PubMed     Text format     Abstract available


  300. SCHERER SD, Bauer J, Schmaus A, Neumaier C, et al
    TGF-beta1 Is Present at High Levels in Wound Fluid from Breast Cancer Patients Immediately Post-Surgery, and Is Not Increased by Intraoperative Radiation Therapy (IORT).
    PLoS One. 2016;11:e0162221.
    PubMed     Text format     Abstract available


  301. TANG S, Wei L, Sun Y, Zhou F, et al
    CA153 in Breast Secretions as a Potential Molecular Marker for Diagnosing Breast Cancer: A Meta Analysis.
    PLoS One. 2016;11:e0163030.
    PubMed     Text format     Abstract available


  302. VITALI F, Cohen LD, Demartini A, Amato A, et al
    A Network-Based Data Integration Approach to Support Drug Repurposing and Multi-Target Therapies in Triple Negative Breast Cancer.
    PLoS One. 2016;11:e0162407.
    PubMed     Text format     Abstract available


  303. WANG Q, Liu L, Li H, Tao P, et al
    Effects of High-Order Interactions among IGFBP-3 Genetic Polymorphisms, Body Mass Index and Soy Isoflavone Intake on Breast Cancer Susceptibility.
    PLoS One. 2016;11:e0162970.
    PubMed     Text format     Abstract available


  304. KRISHNAN P, Ghosh S, Wang B, Heyns M, et al
    Profiling of Small Nucleolar RNAs by Next Generation Sequencing: Potential New Players for Breast Cancer Prognosis.
    PLoS One. 2016;11:e0162622.
    PubMed     Text format     Abstract available


  305. FUKADA I, Araki K, Kobayashi K, Shibayama T, et al
    Predictive Factors and Value of ypN+ after Neoadjuvant Chemotherapy in Clinically Lymph Node-Negative Breast Cancer.
    PLoS One. 2016;11:e0162616.
    PubMed     Text format     Abstract available


  306. FAN LC, Jeng YM, Lu YT, Lien HC, et al
    SPOCK1 Is a Novel Transforming Growth Factor-beta-Induced Myoepithelial Marker That Enhances Invasion and Correlates with Poor Prognosis in Breast Cancer.
    PLoS One. 2016;11:e0162933.
    PubMed     Text format     Abstract available


  307. SUN X, Li Y, Zheng M, Zuo W, et al
    MicroRNA-223 Increases the Sensitivity of Triple-Negative Breast Cancer Stem Cells to TRAIL-Induced Apoptosis by Targeting HAX-1.
    PLoS One. 2016;11:e0162754.
    PubMed     Text format     Abstract available


  308. BRADFORD JR, Cox A, Bernard P, Camp NJ, et al
    Consensus Analysis of Whole Transcriptome Profiles from Two Breast Cancer Patient Cohorts Reveals Long Non-Coding RNAs Associated with Intrinsic Subtype and the Tumour Microenvironment.
    PLoS One. 2016;11:e0163238.
    PubMed     Text format     Abstract available


  309. KOTOULA V, Lakis S, Vlachos IS, Giannoulatou E, et al
    Tumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid Classes.
    PLoS One. 2016;11:e0163138.
    PubMed     Text format     Abstract available


  310. PUCHALAPALLI M, Zeng X, Mu L, Anderson A, et al
    NSG Mice Provide a Better Spontaneous Model of Breast Cancer Metastasis than Athymic (Nude) Mice.
    PLoS One. 2016;11:e0163521.
    PubMed     Text format     Abstract available


  311. ZHANG ZQ, Cao Z, Liu C, Li R, et al
    MiRNA-Embedded ShRNAs for Radiation-Inducible LGMN Knockdown and the Antitumor Effects on Breast Cancer.
    PLoS One. 2016;11:e0163446.
    PubMed     Text format     Abstract available


  312. LEE MH, Jung SY, Kang SH, Song EJ, et al
    The Significance of Serum HER2 Levels at Diagnosis on Intrinsic Subtype-Specific Outcome of Operable Breast Cancer Patients.
    PLoS One. 2016;11:e0163370.
    PubMed     Text format     Abstract available


  313. CHAE JW, Ng T, Yeo HL, Shwe M, et al
    Impact of TNF-alpha (rs1800629) and IL-6 (rs1800795) Polymorphisms on Cognitive Impairment in Asian Breast Cancer Patients.
    PLoS One. 2016;11:e0164204.
    PubMed     Text format     Abstract available


  314. STAVRIDI F, Kalogeras KT, Pliarchopoulou K, Wirtz RM, et al
    Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study.
    PLoS One. 2016;11:e0164013.
    PubMed     Text format     Abstract available


  315. KAWIAK A, Domachowska A
    Plumbagin Suppresses the Invasion of HER2-Overexpressing Breast Cancer Cells through Inhibition of IKKalpha-Mediated NF-kappaB Activation.
    PLoS One. 2016;11:e0164064.
    PubMed     Text format     Abstract available


  316. SAGARA A, Igarashi K, Otsuka M, Karasawa T, et al
    Intrinsic Resistance to 5-Fluorouracil in a Brain Metastatic Variant of Human Breast Cancer Cell Line, MDA-MB-231BR.
    PLoS One. 2016;11:e0164250.
    PubMed     Text format     Abstract available


  317. HORIMOTO Y, Arakawa A, Sasahara N, Tanabe M, et al
    Combination of Cancer Stem Cell Markers CD44 and CD24 Is Superior to ALDH1 as a Prognostic Indicator in Breast Cancer Patients with Distant Metastases.
    PLoS One. 2016;11:e0165253.
    PubMed     Text format     Abstract available


  318. LIU X, Feng D, Liu D, Wang S, et al
    Dissecting the Origin of Breast Cancer Subtype Stem Cell and the Potential Mechanism of Malignant Transformation.
    PLoS One. 2016;11:e0165001.
    PubMed     Text format     Abstract available


  319. LAWRENCE CL, Baldwin AS
    Non-Canonical EZH2 Transcriptionally Activates RelB in Triple Negative Breast Cancer.
    PLoS One. 2016;11:e0165005.
    PubMed     Text format     Abstract available


  320. HREBIEN S, O'Leary B, Beaney M, Schiavon G, et al
    Reproducibility of Digital PCR Assays for Circulating Tumor DNA Analysis in Advanced Breast Cancer.
    PLoS One. 2016;11:e0165023.
    PubMed     Text format     Abstract available


  321. FU J, Wu L, Jiang M, Li D, et al
    Clinical Nomogram for Predicting Survival Outcomes in Early Mucinous Breast Cancer.
    PLoS One. 2016;11:e0164921.
    PubMed     Text format     Abstract available


  322. SLAOUI M, Mouh FZ, Ghanname I, Razine R, et al
    Outcome of Breast Cancer in Moroccan Young Women Correlated to Clinic-Pathological Features, Risk Factors and Treatment: A Comparative Study of 716 Cases in a Single Institution.
    PLoS One. 2016;11:e0164841.
    PubMed     Text format     Abstract available


  323. FORTENBERRY YM, Brandal SM, Carpentier G, Hemani M, et al
    Intracellular Expression of PAI-1 Specific Aptamers Alters Breast Cancer Cell Migration, Invasion and Angiogenesis.
    PLoS One. 2016;11:e0164288.
    PubMed     Text format     Abstract available


  324. ZHANG ZC, Xu QN, Lin SL, Li XY, et al
    Capecitabine in Combination with Standard (Neo)Adjuvant Regimens in Early Breast Cancer: Survival Outcome from a Meta-Analysis of Randomized Controlled Trials.
    PLoS One. 2016;11:e0164663.
    PubMed     Text format     Abstract available


  325. GONZALEZ-BENGTSSON A, Asadi A, Gao H, Dahlman-Wright K, et al
    Estrogen Enhances the Expression of the Polyunsaturated Fatty Acid Elongase Elovl2 via ERalpha in Breast Cancer Cells.
    PLoS One. 2016;11:e0164241.
    PubMed     Text format     Abstract available


  326. HAJIEBRAHIMI M, Montgomery S, Burkill S, Bahmanyar S, et al
    Risk of Premenopausal and Postmenopausal Breast Cancer among Multiple Sclerosis Patients.
    PLoS One. 2016;11:e0165027.
    PubMed     Text format     Abstract available


  327. ZHANG Z, Luo G, Tang H, Cheng C, et al
    Prognostic Significance of High VEGF-C Expression for Patients with Breast Cancer: An Update Meta Analysis.
    PLoS One. 2016;11:e0165725.
    PubMed     Text format     Abstract available


  328. HAN YJ, Zhang J, Zheng Y, Huo D, et al
    Genetic and Epigenetic Regulation of TOX3 Expression in Breast Cancer.
    PLoS One. 2016;11:e0165559.
    PubMed     Text format     Abstract available


  329. HYUN SH, Ahn HK, Lee JH, Choi JY, et al
    Body Mass Index with Tumor 18F-FDG Uptake Improves Risk Stratification in Patients with Breast Cancer.
    PLoS One. 2016;11:e0165814.
    PubMed     Text format     Abstract available


  330. CHEN HL, Zhou MQ, Tian W, Meng KX, et al
    Effect of Age on Breast Cancer Patient Prognoses: A Population-Based Study Using the SEER 18 Database.
    PLoS One. 2016;11:e0165409.
    PubMed     Text format     Abstract available


  331. GREGORIO AC, Fonseca NA, Moura V, Lacerda M, et al
    Inoculated Cell Density as a Determinant Factor of the Growth Dynamics and Metastatic Efficiency of a Breast Cancer Murine Model.
    PLoS One. 2016;11:e0165817.
    PubMed     Text format     Abstract available


  332. CHEN B, Dai D, Tang H, Ai X, et al
    Pretreatment Hematocrit Is Superior to Hemoglobin as a Prognostic Factor for Triple Negative Breast Cancer.
    PLoS One. 2016;11:e0165133.
    PubMed     Text format     Abstract available


  333. SHIOTA T, Miyasato Y, Ohnishi K, Yamamoto-Ibusuki M, et al
    The Clinical Significance of CD169-Positive Lymph Node Macrophage in Patients with Breast Cancer.
    PLoS One. 2016;11:e0166680.
    PubMed     Text format     Abstract available


  334. HANIEH H, Mohafez O, Hairul-Islam VI, Alzahrani A, et al
    Novel Aryl Hydrocarbon Receptor Agonist Suppresses Migration and Invasion of Breast Cancer Cells.
    PLoS One. 2016;11:e0167650.
    PubMed     Text format     Abstract available


  335. GROSSET AA, Poirier F, Gaboury L, St-Pierre Y, et al
    Galectin-7 Expression Potentiates HER-2-Positive Phenotype in Breast Cancer.
    PLoS One. 2016;11:e0166731.
    PubMed     Text format     Abstract available


  336. SCOTT CM, Joo JE, O'Callaghan N, Buchanan DD, et al
    Methylation of Breast Cancer Predisposition Genes in Early-Onset Breast Cancer: Australian Breast Cancer Family Registry.
    PLoS One. 2016;11:e0165436.
    PubMed     Text format     Abstract available


  337. WU Z, Liu Y, Li X, Li X, et al
    Resilience and Associated Factors among Mainland Chinese Women Newly Diagnosed with Breast Cancer.
    PLoS One. 2016;11:e0167976.
    PubMed     Text format     Abstract available


  338. GERNAAT SA, Isgum I, de Vos BD, Takx RA, et al
    Automatic Coronary Artery Calcium Scoring on Radiotherapy Planning CT Scans of Breast Cancer Patients: Reproducibility and Association with Traditional Cardiovascular Risk Factors.
    PLoS One. 2016;11:e0167925.
    PubMed     Text format     Abstract available


  339. VAN HELMOND N, Steegers MA, Filippini-de Moor GP, Vissers KC, et al
    Hyperalgesia and Persistent Pain after Breast Cancer Surgery: A Prospective Randomized Controlled Trial with Perioperative COX-2 Inhibition.
    PLoS One. 2016;11:e0166601.
    PubMed     Text format     Abstract available


  340. TANINO H, Kosaka Y, Nishimiya H, Tanaka Y, et al
    BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    PLoS One. 2016;11:e0165721.
    PubMed     Text format     Abstract available


  341. YEH TC, Huang TT, Yeh TS, Chen YR, et al
    miR-151-3p Targets TWIST1 to Repress Migration of Human Breast Cancer Cells.
    PLoS One. 2016;11:e0168171.
    PubMed     Text format     Abstract available


  342. PARK SY, Choi CH, Park JM, Chun M, et al
    A Patient-Specific Polylactic Acid Bolus Made by a 3D Printer for Breast Cancer Radiation Therapy.
    PLoS One. 2016;11:e0168063.
    PubMed     Text format     Abstract available


  343. HELLWIG B, Madjar K, Edlund K, Marchan R, et al
    Epsin Family Member 3 and Ribosome-Related Genes Are Associated with Late Metastasis in Estrogen Receptor-Positive Breast Cancer and Long-Term Survival in Non-Small Cell Lung Cancer Using a Genome-Wide Identification and Validation Strategy.
    PLoS One. 2016;11:e0167585.
    PubMed     Text format     Abstract available


  344. FERNANDEZ-GALLARDO M, Gonzalez-Ramirez R, Sandoval A, Felix R, et al
    Adenosine Stimulate Proliferation and Migration in Triple Negative Breast Cancer Cells.
    PLoS One. 2016;11:e0167445.
    PubMed     Text format     Abstract available


  345. KOTWINSKI P, Smith G, Cooper J, Sanders J, et al
    Body Surface Area and Baseline Blood Pressure Predict Subclinical Anthracycline Cardiotoxicity in Women Treated for Early Breast Cancer.
    PLoS One. 2016;11:e0165262.
    PubMed     Text format     Abstract available


  346. KANG EJ, Seo JH, Kim LY, Park GU, et al
    Pregnancy-Associated Risk Factors of Postpartum Breast Cancer in Korea: A Nationwide Health Insurance Database Study.
    PLoS One. 2016;11:e0168469.
    PubMed     Text format     Abstract available


  347. LIU H, Wang G, Yang L, Qu J, et al
    Knockdown of Long Non-Coding RNA UCA1 Increases the Tamoxifen Sensitivity of Breast Cancer Cells through Inhibition of Wnt/beta-Catenin Pathway.
    PLoS One. 2016;11:e0168406.
    PubMed     Text format     Abstract available


  348. TOKUNAGA E, Yamashita N, Tanaka K, Inoue Y, et al
    Expression of APOBEC3B mRNA in Primary Breast Cancer of Japanese Women.
    PLoS One. 2016;11:e0168090.
    PubMed     Text format     Abstract available


  349. MORI H, Kubo M, Nishimura R, Osako T, et al
    BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer.
    PLoS One. 2016;11:e0167016.
    PubMed     Text format     Abstract available


  350. LIN J, Chen DR, Wang YF, Lai HW, et al
    Oncoplastic Surgery for Upper/Upper Inner Quadrant Breast Cancer.
    PLoS One. 2016;11:e0168434.
    PubMed     Text format     Abstract available


  351. FARAJI A, Dehghan Manshadi HR, Mobaraki M, Zare M, et al
    Association of ABCB1 and SLC22A16 Gene Polymorphisms with Incidence of Doxorubicin-Induced Febrile Neutropenia: A Survey of Iranian Breast Cancer Patients.
    PLoS One. 2016;11:e0168519.
    PubMed     Text format     Abstract available


  352. WU ZH, Lin C, Liu MM, Zhang J, et al
    Src Inhibition Can Synergize with Gemcitabine and Reverse Resistance in Triple Negative Breast Cancer Cells via the AKT/c-Jun Pathway.
    PLoS One. 2016;11:e0169230.
    PubMed     Text format     Abstract available


  353. GHOSH K, De S, Das S, Mukherjee S, et al
    Withaferin A Induces ROS-Mediated Paraptosis in Human Breast Cancer Cell-Lines MCF-7 and MDA-MB-231.
    PLoS One. 2016;11:e0168488.
    PubMed     Text format     Abstract available


  354. JIAO C, Cui L, Ma A, Li N, et al
    Elevated Serum Levels of Retinol-Binding Protein 4 Are Associated with Breast Cancer Risk: A Case-Control Study.
    PLoS One. 2016;11:e0167498.
    PubMed     Text format     Abstract available


  355. CAMPBELL TM, Castro MA, Ponder BA, Meyer KB, et al
    Identification of Post-Transcriptional Modulators of Breast Cancer Transcription Factor Activity Using MINDy.
    PLoS One. 2016;11:e0168770.
    PubMed     Text format     Abstract available


  356. REINERI S, Agati S, Miano V, Sani M, et al
    A Novel Functional Domain of Tab2 Involved in the Interaction with Estrogen Receptor Alpha in Breast Cancer Cells.
    PLoS One. 2016;11:e0168639.
    PubMed     Text format     Abstract available


  357. DIESSNER J, Wischnewsky M, Blettner M, Hausler S, et al
    Do Patients with Luminal A Breast Cancer Profit from Adjuvant Systemic Therapy? A Retrospective Multicenter Study.
    PLoS One. 2016;11:e0168730.
    PubMed     Text format     Abstract available


  358. KAZMIERCZAK PM, Todica A, Gildehaus FJ, Hirner-Eppeneder H, et al
    68Ga-TRAP-(RGD)3 Hybrid Imaging for the In Vivo Monitoring of alphavss3-Integrin Expression as Biomarker of Anti-Angiogenic Therapy Effects in Experimental Breast Cancer.
    PLoS One. 2016;11:e0168248.
    PubMed     Text format     Abstract available


  359. BURKE NJ, Napoles TM, Banks PJ, Orenstein FS, et al
    Survivorship Care Plan Information Needs: Perspectives of Safety-Net Breast Cancer Patients.
    PLoS One. 2016;11:e0168383.
    PubMed     Text format     Abstract available


  360. FERRARIO C, Strepponi I, Esfahani K, Charamis H, et al
    Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer.
    PLoS One. 2016;11:e0167906.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: